is-1

1

1

1

1

1

1

1

1

1

1

1

ABOUT US

NograDerm is a late-stage pharmaceutical company focused on developing innovative treatments for immune-inflammatory mediated dermatological diseases and conditions.
Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat dermatological diseases and disorders. Our management team has extensive expertise to identify, develop and commercialize best-in-class molecules acting on validated targets.

Discover more

OUR FOCUS

Dermatological diseases affect millions of people worldwide each year, impacting their quality of life, and emotional well-being. Despite this, and despite progress in the development of biologic therapies to treat dermatological diseases, the vast majority of dermatology patients continue to be treated by older therapies that often do not provide adequate efficacy, do not target specific disease mediators, or that carry with them substantial safety and tolerability issues.

Dermatologists and patients need innovative topical treatments that target validated molecular mediators of disease with high local skin efficacy, low systemic and topical safety risks, the ability to use chronically, and with a good high risk/benefit ratio.

Acne Pathogenesis

Discover more

Psoriasis Pathogenesis

Discover more

Potential Indications

Discover more

References

Discover more

R&D

NograDerm is focused on the development of new therapeutic agents for the treatment and management of Immune-Mediated Inflammatory Diseases from target validation up to Phase III clinical studies.

NograDerma’s business model is to establish long and fruitful partnerships for its R&D pipeline both with Universities/Research Institutes to source innovative targets and with pharma/biotech companies for the completion of the development process and commercialization.

Thanks to the strong network of collaborations with both Academia and leading KOLs, NograDerm is able to identify development programs in its core R&D areas, to take through to Clinical Development.

Discover more